Showing 19,621 - 19,640 results of 21,342 for search '(( significant a decrease ) OR ( ((significant decrease) OR (significantly increased)) decrease ))', query time: 0.64s Refine Results
  1. 19621

    Light avoidance requires the cGMP-dependent pathway in <i>P</i>. <i>pacificus</i>. by Kenichi Nakayama (2354653)

    Published 2024
    “…These mutants had decreased light-induced avoidance response. (B) List of predicted causal genes. …”
  2. 19622

    Table 1_Spatial yield gains in empty-row optimized rice–crab co-culture are linked to nifH-driven nitrogen compensation in border rows.docx by Tiexin Yang (21423032)

    Published 2025
    “…</p>Results<p>Our results showed that although ERC-12 increased per-plant yield via marginal effects in the boundary zone (PB), total yield decreased by 4.06%-5.20% compared to CK, primarily due to yield losses in the intermediate zone (PM) and empty rows. …”
  3. 19623

    Gastric microbiome composition accompanied with the <i>Helicobacter pylori</i> related DNA methylation anomaly by Takuya Shijimaya (16928363)

    Published 2024
    “…Multivariate analysis demonstrated older age (t = 3.46, <i>p</i> = 0.0007), <i>H. pylori</i> infection (t = 9.99, <i>p</i> < 0.0001) and lower bacterial alfa diversity (Shannon index: t = -2.34, <i>p</i> = 0.02) were significantly associated with CGI hypermethylation. In genus or family levels, increased abundance of <i>Helicobacter</i> was associated with hyper CGI methylation with strongest correlation, while decreased abundance of four bacteria (<i>Intrasporangiaceae family, Macellibacteroides</i>, <i>Peptostreptococcus</i> and <i>Dietziaceae family</i>) was also associated with hyper CGI methylation. …”
  4. 19624

    Table 4_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xls by Guilin Ren (18720749)

    Published 2025
    “…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”
  5. 19625

    Table 2_Identification of metabolic pathways modulated by GAM and NGAM in the inhibition of Staphylococcus aureus biofilm formation.xlsx by Amirmohammad Afsharnia (22569827)

    Published 2025
    “…<p>The prevalence of antibiotic-resistant bacterial strains, particularly Staphylococcus aureus, poses a significant threat to global health. The ability of S. aureus to form biofilms reduces the efficacy of antibiotics. …”
  6. 19626

    Image 1_Identification of metabolic pathways modulated by GAM and NGAM in the inhibition of Staphylococcus aureus biofilm formation.jpeg by Amirmohammad Afsharnia (22569827)

    Published 2025
    “…<p>The prevalence of antibiotic-resistant bacterial strains, particularly Staphylococcus aureus, poses a significant threat to global health. The ability of S. aureus to form biofilms reduces the efficacy of antibiotics. …”
  7. 19627

    Data Sheet 1_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.doc by Guilin Ren (18720749)

    Published 2025
    “…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”
  8. 19628

    Table 2_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xlsx by Guilin Ren (18720749)

    Published 2025
    “…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”
  9. 19629

    Table 7_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xlsx by Guilin Ren (18720749)

    Published 2025
    “…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”
  10. 19630

    Table 1_Identification of metabolic pathways modulated by GAM and NGAM in the inhibition of Staphylococcus aureus biofilm formation.xlsx by Amirmohammad Afsharnia (22569827)

    Published 2025
    “…<p>The prevalence of antibiotic-resistant bacterial strains, particularly Staphylococcus aureus, poses a significant threat to global health. The ability of S. aureus to form biofilms reduces the efficacy of antibiotics. …”
  11. 19631

    original data.xlsx by Peng Shen (20145351)

    Published 2024
    “…<b>Research Results</b>: The results showed that the levels of inflammatory factors significantly decreased in the blood purification treatment group after treatment, with a notable reduction in hospitalization and ICU stay duration compared to the conventional treatment group. …”
  12. 19632

    Data Sheet 1_Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients.pdf by Maria Delgado-Ortet (8840702)

    Published 2025
    “…Background<p>High-grade serous carcinoma is a highly metastatic disease with a limited longterm disease control from systemic anti-cancer treatment, for which the radiological treatment response assessment metrics are imprecise. …”
  13. 19633

    Table 1_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xlsx by Guilin Ren (18720749)

    Published 2025
    “…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”
  14. 19634

    Table 3_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xlsx by Guilin Ren (18720749)

    Published 2025
    “…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”
  15. 19635

    Data Sheet 1_Case Report: Dual immunomodulatory and hematologic benefits of rituximab in refractory anemia of ANCA-associated vasculitis.docx by Ningjun Shao (20748705)

    Published 2025
    “…Despite conventional immunosuppressive therapies, refractory anemia remains a significant challenge, with limited strategies targeting inflammation-driven hepcidin dysregulation.…”
  16. 19636

    Data Sheet 2_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.docx by Guilin Ren (18720749)

    Published 2025
    “…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”
  17. 19637

    Table 6_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xlsx by Guilin Ren (18720749)

    Published 2025
    “…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”
  18. 19638

    Table 5_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xls by Guilin Ren (18720749)

    Published 2025
    “…Introduction<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by excessive lipid deposition in hepatocytes without a history of significant alcohol consumption. Pachymic acid (Pac), a bioactive triterpenoid from Poria cocos, has shown promise in treating MASLD due to its antioxidant and anti-inflammatory capabilities. …”
  19. 19639

    Data Sheet 1_Gram-positive enhancer matrix delivering FVpE via M cell targeting elicit protective mucosal and adaptive immune responses against Helicobacter pylori infection.doc by Furui Zhang (3181935)

    Published 2025
    “…Meanwhile, GEM-SAM-FVpE enhances antigen presentation efficiency and activates DCs by upregulating MHC II and costimulatory molecules (CD80/CD86/CD40), and increasing the secretion of related cytokines. In vivo experiments indicate that oral administration of the GEM-SAM-FVpE significantly induces the production of high titers of sIgA, serum IgG, and its subtype, initiating mucosal and humoral immune responses, and inhibiting the adhesion of H. pylori to normal gastric mucosal epithelial cells. …”
  20. 19640

    Table_1_Effect of diet low in omega-6 polyunsaturated fatty acids on the global burden of cardiovascular diseases and future trends: evidence from the Global Burden of Disease 2021... by Qingsong Mao (19522438)

    Published 2025
    “…The most significant effects were seen in individuals aged 75 and older, with a higher disease burden noted in males. …”